Skip to content

US · PMN · BIOTECHNOLOGY

ProMIS Neurosciences, Inc. (PMN) intrinsic value and stock valuation

$3.16as of 2026-11-21 · Mkt cap 17.63M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

ProMIS Neurosciences, Inc. DCF and intrinsic value

InvestorsCraft values PMN with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from PMN’s statements →

ProMIS Neurosciences, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Toronto, ON M4S 3E2 promisneurosciences.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$0.00
20112025
Net income
-$-39.72M
20112025
Free cash flow
-$-28.12M
20112025
Total equity
-$-1.26M
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$20K
Operating income-$-40.17M-$-16.83M-$-18.9M-$-31.41M-$-10.57M
Net income-$-39.72M$2.78M-$-17.51M-$-24.27M-$-11.98M
EPSd-$-22.61K$2.62M-$-35.73M-$-80.9M-$-52.09M
Operating cash flow-$-28.12M-$-27.18M-$-10.84M-$-22.89M-$-9.44M
Capital expenditure$0.00$0.00$0.00-$0.00-$-10K
Free cash flow-$-28.12M-$-27.18M-$-10.84M-$-22.89M-$-9.45M
Total assets$9.18M$18.9M$13.6M$12.6M$22.4M
Total debt$0.00$0.00$0.00$0.00$4.94M
Net debt-$-6.12M-$-13.29M-$-12.6M-$-10.69M-$-16.49M
Total equity-$-1.26M$16.5M$3.75M-$-2.45M$7.16M
Cash and short-term investments$6.15M$13.3M$12.6M$10.8M$21.5M
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$20K
Cost of revenue$33.4M$0.00$10.4M$20K$5.85M
Gross profit-$-33.36M$0.00-$-10.44M-$-20K-$-5.84M
Research and development expenses$33.4M$10.6M$7.88M$21.6M$4.95M
Selling, general and administrative expenses$6.79M$6.19M$6.38M$9.8M$3.31M
Other expenses$0.00$0.00-$-5.81M$0.00-$-3.63M
Operating expenses$40.2M$16.8M$8.45M$31.4M$4.63M
Cost and expenses$40.2M$16.8M$18.9M$31.4M$10.9M
Interest income$0.00$0.00$0.00$0.00$0.00
Interest expense$0.00$80K$200K$380K$420K
Depreciation and amortization-$-720K$0.00$30K$20K$50K
Ebitda-$-39.72M$2.86M-$-17.81M-$-23.88M-$-9.33M
Operating income-$-40.17M-$-16.83M-$-18.9M-$-31.41M-$-10.57M
Total other income/expenses, net$450K$19.6M$1.39M$7.15M-$-1.91M
Income before tax-$-39.72M$2.78M-$-17.51M-$-24.27M-$-12.48M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-39.72M$2.78M-$-17.51M-$-24.27M-$-11.98M
Weighted average shares outstanding$1.76B$1.04M$490K$300K$230K
Weighted average diluted shares outstanding$1.76B$1.06M$490K$300K$230K
Balance sheet
20252024202320222021
Cash and short-term investments$6.15M$13.3M$12.6M$10.8M$21.5M
Net receivables$40K$80K$80K$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$9.18M$18.9M$13.6M$12.6M$22.4M
Property, plant and equipment, net$0.00$0.00$0.00$0.00$10K
Goodwill and intangible assets$0.00$0.00$0.00$40K$30K
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$0.00$0.00$0.00$40K$40K
Total assets$9.18M$18.9M$13.6M$12.6M$22.4M
Accounts payable$2.54M$1.74M$7.84M$5.41M$520K
Short-term debt$0.00$0.00$0.00$0.00$0.00
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$10.4M$2.22M$9.35M$11.7M$1.17M
Long-term debt$0.00$0.00$0.00$0.00$4.94M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$30K$200K$520K$3.38M$14.1M
Capital lease obligations$0.00$0.00$0.00$0.00$0.00
Total liabilities$10.4M$2.42M$9.87M$15.1M$15.3M
Common stock$0.00$0.00$0.00$0.00$0.00
Retained earnings-$-130.41M-$-90.69M-$-93.47M-$-146M-$-78.64M
Accumulated other comprehensive income (loss)-$-370K-$-370K-$-370K-$-360K-$-240K
Total equity-$-1.26M$16.5M$3.75M-$-2.45M$7.16M
Total investments$30K$30K$30K$80K$50K
Total debt$0.00$0.00$0.00$0.00$4.94M
Net debt-$-6.12M-$-13.29M-$-12.6M-$-10.69M-$-16.49M
Cash flow statement
20252024202320222021
Net income-$-39.72M$2.78M-$-13.21M-$-24.27M-$-9.4M
Depreciation and amortization$0.00$0.00$20K$20K$50K
Stock-based compensation$860K$830K$270K$660K$0.00
Change in working capital$10.8M-$-11.73M$2.94M$7.26M-$-1.59M
Accounts receivable$0.00$0.00$0.00$0.00-$-20K
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$810K-$-6.11M$4.96M$3.6M-$-30K
Net cash provided by operating activities-$-28.12M-$-27.18M-$-10.84M-$-22.89M-$-9.44M
Investments in property, plant and equipment$0.00$0.00$0.00-$0.00-$-10K
Acquisitions, net$0.00$0.00$0.00$0.00$100K
Net cash used for investing activities-$0.00-$0.00-$0.00-$0.00$100K
Common stock issued$20.9M$27.9M$17.8M$6.68M$25.6M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$20.9M$27.9M$17.8M$8.73M$25.6M
Net change in cash-$-7.17M$690K$6.72M-$-14.87M$16.2M
Cash at end of period$6.12M$13.3M$12.6M$7.89M$17M
Operating cash flow-$-28.12M-$-27.18M-$-10.84M-$-22.89M-$-9.44M
Capital expenditure$0.00$0.00$0.00-$0.00-$-10K
Free cash flow-$-28.12M-$-27.18M-$-10.84M-$-22.89M-$-9.45M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About ProMIS Neurosciences, Inc.

        ProMIS Neurosciences, Inc. is a Canadian biotechnology firm dedicated to creating targeted therapeutic solutions for debilitating neurodegenerative conditions such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company leverages a unique computational discovery platform, utilizing its ProMIS and Collective Coordinates algorithms, to identify novel, disease-specific targets – known as epitopes – located on the surface of misfolded proteins. Its pipeline features several promising drug candidates, including PMN310, a monoclonal antibody designed to address toxic oligomers implicated in Alzheimer's disease. Another candidate, PMN267, targets superoxide dismutase 1 and TAR-DNA binding protein 43 in ALS, and alpha-synuclein associated with Parkinson's disease and Lewy body dementia. Finally, PMN442 is a monoclonal antibody aimed at toxic alpha-synuclein oligomers and seeding fibrils relevant to multiple system atrophy. Established in 2004, the company changed its name from Amorfix Life Sciences Ltd. to ProMIS Neurosciences, Inc. in July 2015. Its corporate headquarters are situated in Toronto, Canada.

        CEO
        Neil K. Warma
        Employees
        11
        Beta
        -0.21

        Explore

        Frequently asked questions

        What is the intrinsic value of ProMIS Neurosciences, Inc. (PMN)?

        InvestorsCraft does not currently publish an intrinsic value for PMN. How the IC value is calculated.

        Is PMN undervalued?

        InvestorsCraft does not publish an undervaluation signal for PMN at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.